Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences, Inc. is trading at $26.22, up 1.22% on the session. The 50 day average sits at $25.20 and the 200 day at $23.77, which puts the stock in a uptrend. RSI is at 57.6, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $24.61 with resistance near $26.21, so that band frames the current range. Average daily movement is roughly $0.83, or about 3.2% of the share price, which is what any stop placement has to allow for. The overall health score of 71 out of 100 combines a trend score of 81, momentum of 74 and a risk score of 50.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.